Otsuka to take over Astellas’ Cefixime business

pharmafile | June 7, 2019 | News story | Medical Communications APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma 

Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime.

The agreement gives Otsuka the right to sell Cefixime and supply the active pharmaceutical ingredient (API) to overseas licensees.

The move comes as part of an effort from Otsuka to strengthen their grounding in the API business.

Astellas’ Cefixime is a third generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria. The antibiotic is prescribed around the world.

Otsuka said they intend to further strengthen their business through new technologies as they take advantage of key technologies.

Louis Goss

Related Content

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content